4882 Stock Overview
A drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Perseus Proteomics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥640.00 |
| 52 Week High | JP¥879.00 |
| 52 Week Low | JP¥291.00 |
| Beta | 0.70 |
| 11 Month Change | 4.75% |
| 3 Month Change | 0.31% |
| 1 Year Change | 42.22% |
| 33 Year Change | 36.75% |
| 5 Year Change | n/a |
| Change since IPO | -26.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4882 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 7.2% | 2.0% | 3.2% |
| 1Y | 42.2% | 33.5% | 15.2% |
Return vs Industry: 4882 exceeded the JP Biotechs industry which returned 33.5% over the past year.
Return vs Market: 4882 exceeded the JP Market which returned 15.2% over the past year.
Price Volatility
| 4882 volatility | |
|---|---|
| 4882 Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in JP Market | 7.7% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4882's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4882's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 25 | Takuya Yokokawa | www.ppmx.com |
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate.
Perseus Proteomics Inc. Fundamentals Summary
| 4882 fundamental statistics | |
|---|---|
| Market cap | JP¥9.41b |
| Earnings (TTM) | -JP¥901.00m |
| Revenue (TTM) | JP¥96.00m |
98.2x
P/S Ratio-10.5x
P/E RatioIs 4882 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4882 income statement (TTM) | |
|---|---|
| Revenue | JP¥96.00m |
| Cost of Revenue | JP¥11.00m |
| Gross Profit | JP¥85.00m |
| Other Expenses | JP¥986.00m |
| Earnings | -JP¥901.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 14, 2024
| Earnings per share (EPS) | -61.17 |
| Gross Margin | 88.54% |
| Net Profit Margin | -938.54% |
| Debt/Equity Ratio | 0% |
How did 4882 perform over the long term?
See historical performance and comparison